Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 183 clinical trials
None
Clofarabine Idarubicin Cytarabine Vincristine Sulfate and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

This phase II trial studies how well clofarabine, idarubicin, cytarabine, vincristine sulfate, and dexamethasone work in treating patients with mixed phenotype acute leukemia that is newly

dexamethasone
ejection fraction
myeloid leukemia
rituximab
cancer
  • 22 views
  • 05 Nov, 2021
  • 1 location
None
A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol

hematological malignancies. This finding deserves to be tested in prospective clinical trials with long-term follow-up. Cytarabine has been applied for patients with LCH but has never been evaluated in our

  • 0 views
  • 06 Mar, 2021
  • 1 location
None
Liposomal Cytarabine Daunorubicin and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

This phase I trial studies the best dose and side effects of liposomal cytarabine, daunorubicin, and gemtuzumab ozogamicin in treating pediatric patients with acute myeloid leukemia that has

  • 0 views
  • 13 Jun, 2021
  • 1 location
None
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission

This phase 2, open label, non-randomized study will evaluate the safety of administering high dose cytarabine (HiDAC) consolidation therapy on days 1-3 of each cycle, as compared to standard

induction chemotherapy
blast cells
consolidation therapy
remission
cytarabine
  • 0 views
  • 24 Nov, 2021
  • 1 location
None
Uproleselan Cladribine and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

This phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute

  • 0 views
  • 05 Jul, 2021
  • 1 location
None
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

group receive high-dose cytarabine(HDAC) regimen while the experimental group receive high dose of cytarabine plus tretinoin(ATRA) and arsenic trioxide(ATO) treatment.The safety and efficacy of ATRA and

tretinoin
cytarabine
  • 43 views
  • 24 Jan, 2021
  • 1 location
None
Efficacy and Safety of Chidamide in CBF Leukemia

In this open-label, randomized, prospective clinical trial, CBF acute myeloid leukemia (AML) patients who have reached CR are randomised into two groups and receive high-dose cytarabine (HDAC

cytarabine
  • 35 views
  • 23 Jan, 2021
None
The Application of a Portable Multichannel ECG System for the Patients Suspected to Have Possible CAD or ACS

This clinical trial is to test if a 28-channel ECG (MECG) system would efficiently differentiate the patients suspected to have CAD or ACS with acceptable sensitivity and specificity, and optimize this portable self-built-in multichannel ECG recorder system with various algorithms. The 28-channel ECG (MECG) system is a multi-channel real-time cardiovascular …

  • 0 views
  • 18 Mar, 2021
  • 1 location
None
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML

Rencent years have witnessed great progress of the treatment of acute myeloid leukemia. However, most patients have poor outcomes following the currently first-line DA(daunorubicin, cytarabine

azacitidine
filgrastim
daunorubicin
granulocyte colony stimulating factor
colony stimulating factor
  • 0 views
  • 25 Jan, 2021
  • 1 location
None
Cladribine Idarubicin Cytarabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia High-Risk Myelodysplastic Syndrome or Blastic Phase Chronic Myeloid Leukemia

This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic

azacitidine
ejection fraction
myeloid leukemia
venetoclax
secondary acute myeloid leukemia
  • 42 views
  • 25 Jan, 2021
  • 1 location